Kolexia
Schraen Susanna Pharmacien
Schraen Susanna
Pharmacien
Hôpital Albert Calmette
Lille, France
121 Activités
3 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie d'Alzheimer Démence Myélome multiple Dystrophie myotonique Maladies neurodégénératives Tauopathies Inflammation Atrophie Hémorragie cérébrale

Collaborateurs

Voir plus
Lehmann Sylvain
Lehmann Sylvain
Hôpital Saint-Éloi, Montpellier, France
Gabelle Audrey
Gabelle Audrey
Hôpital Gui de Chauliac, Montpellier, France
Pasquier-Garguillo Florence
Pasquier-Garguillo Florence
Hôpital Roger Salengro, Lille, France
Bombois Stephanie
Bombois Stephanie
Hôpital Pitie Salpetriere, Paris, France

Industries

Voir plus
{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
The free plasma amyloid Aβ /Aβ ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma Aβ /Aβ ratio. The BALTAZAR study.
Neurobiology of disease   27 février 2024
Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum.
International journal of molecular sciences   11 décembre 2023
Head-to-Head Comparison of Two Plasma Phospho-tau Assays in Predicting Conversion of Mild Cognitive Impairment to Dementia.
Clinical chemistry   04 septembre 2023
Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function.
Journal of neurology, neurosurgery, and psychiatry   03 avril 2023
Plasma Aβ42/Aβ40 ratio is independent of renal function.
Alzheimer's & dementia : the journal of the Alzheimer's Association   12 février 2023
Neurofilaments: a key new biomarker for clinicians. Part 2: Neurofilaments, an asset beyond neurodegenerative diseases.
Annales de biologie clinique   02 décembre 2022
Neurofilaments: a key new biomarker for clinicians. Part 1: Importance of neurofilaments in the management of neurodegenerative diseases.
Annales de biologie clinique   02 décembre 2022
Neurofilaments contribution in clinic: state of the art.
Frontiers in aging neuroscience   01 novembre 2022
Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
Neurology   26 mai 2022
A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
Neurology   26 mai 2022